Clinical Trial Update: XK469R in Treating Patients With Refractory Hematologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting initial safety and tolerability findings for XK469R in patients with refractory hematologic cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Basophilic Leukemia
• Chronic Lymphocytic Leukemia
• Eosinophilic Leukemia
• Erythroleukemia
• Myelodysplastic Syndromes
• Myelogenous Leukemia

Drugs mentioned

• XK469R (XK469R)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Status: COMPLETED